GlassScriptPhysician profile
Michael W Heniff
NPI 1790724417
$8,773.80
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,345 · 2020: $2,759 · 2021: $1,847 · 2022: $118 · 2023: $515 · 2024: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,418.71 | 2019-2024 | Tezspire, Breztri, Symbicort |
| Glaxosmithkline, LLC. | $1,464.80 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $698.64 | 2019-2021 | |
| Genentech USA, INC. | $476.49 | 2019-2022 | |
| Mylan Specialty L.P. | $463.84 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $387.51 | 2019-2021 | |
| Pfizer INC. | $381.58 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $272.51 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $221.95 | 2019-2021 | |
| Amgen INC. | $210.30 | 2022-2024 | Tezspire |
| Arbor Pharmaceuticals, INC. | $175.28 | 2019-2021 | |
| Genzyme Corporation | $144.95 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $143.88 | 2019-2022 | |
| Novo Nordisk INC | $143.24 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $126.20 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $105.90 | 2019-2021 | |
| Allergan, INC. | $105.83 | 2019 | |
| Abbvie INC. | $97.69 | 2021-2023 | |
| Insmed, INC. | $78.35 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.71 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $72.70 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $66.28 | 2019-2021 | |
| Baxter Healthcare | $63.92 | 2020-2023 | Hillrom - Life 2000 Ventilation System |
| Mallinckrodt Hospital Products INC. | $61.76 | 2021 | |
| Circassia INC. | $57.93 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $54.91 | 2019 | |
| Eisai INC. | $34.03 | 2021 | |
| Hikma Pharmaceuticals USA | $31.20 | 2019-2021 | |
| Advanced Respiratory, INC | $30.16 | 2020 | |
| Philips North America LLC | $19.54 | 2019 | |
| Inogen, INC. | $19.08 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Nabriva Therapeutics, Plc | $18.37 | 2021 | |
| Aytu Biopharma, INC. | $18.00 | 2020 | |
| Eyevance Pharmaceuticals LLC | $17.56 | 2021 | |
| Lilly USA, LLC | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Heniff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.